AMD3100 for Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells

Phase 2, open-label trial of plerixafor in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and 5 more (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Proportion of Donors From Whom a Sufficient Number of Cells for Transplantation Are Collected in no More Than 2 LP Procedures Following Mobilization With AMD3100, Proportion of Recipients Who Experience Grade 2-4 Acute GVHD at Day 100 and 1 more. Started May 2004; status: completed.